Avenzo Therapeutics
PrivateLast Round
Private Placement
Jun 1, 2026
Est. Valuation
$515M
Total Funding Raised
$792.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Avenzo Therapeutics is a biotechnology company that develops next-generation oncology therapies, including small-molecule inhibitors and antibody-drug conjugates, for patients with cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Avenzo Therapeutics Comparables
Compare Avenzo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Incyclix Bio | 86% | |
| NiKang Therapeutics | 81% | |
| Pyxa Pharmaceuticals | 80% |
Avenzo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jun 1, 2026 | ||||
| Series B | Sep 22, 2025 | ||||
| Series A | Nov 18, 2024 | ||||
| Series A Extension | Mar 26, 2024 | ||||
| Series A | May 25, 2023 |
Key People
Founding team and executive leadership
Avenzo Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Surveyor Capital | Private Placement, Series A Extension, Series A, Series B |
| New Enterprise Associates (NEA) | Private Placement, Series B, Series A Extension, Series A |
| TF Capital | Series A Extension, Series A, Series B |
| 渶策资本 | Series A Extension, Series A, Series B |
| Deep Track Capital | Private Placement, Series B, Series A Extension, Series A |
| OrbiMed | Private Placement, Series A Extension, Series A, Series B |
| Foresite Capital | Private Placement, Series A Extension, Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 80% MoM, reaching 7.7K.
- Jun 1, 2026
$215M round with participation from NEA and Blackstone.
Avenzo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Avenzo Therapeutics's valuation, stock price, and market status.
Is Avenzo Therapeutics a public or private company?
Avenzo Therapeutics is a private company.
What is the current stock price of Avenzo Therapeutics?
Avenzo Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Avenzo Therapeutics worth (valuation)?
Valuation information for Avenzo Therapeutics is not publicly available.
Can I buy Avenzo Therapeutics stock?
Avenzo Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Avenzo Therapeutics's last funding round?
Avenzo Therapeutics's most recent funding round was Series B on September 22, 2025.
Who are the main investors in Avenzo Therapeutics?
Key investors in Avenzo Therapeutics include New Enterprise Associates (NEA), Deep Track Capital, OrbiMed, SR One, Sands Capital.
Will Avenzo Therapeutics IPO soon?
No public IPO plans have been announced for Avenzo Therapeutics.
How can I track Avenzo Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Avenzo Therapeutics's secondary market activity and sign up for updates.